B & T Capital Management DBA Alpha Capital Management Has $4.29 Million Holdings in Kenvue Inc. (NYSE:KVUE)

B & T Capital Management DBA Alpha Capital Management raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 1.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 200,967 shares of the company’s stock after purchasing an additional 3,009 shares during the quarter. B & T Capital Management DBA Alpha Capital Management’s holdings in Kenvue were worth $4,291,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in KVUE. State Street Corp raised its holdings in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after buying an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after purchasing an additional 7,115,374 shares during the last quarter. Holocene Advisors LP lifted its holdings in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares during the period. M&G PLC lifted its stake in shares of Kenvue by 538.0% in the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after purchasing an additional 3,660,730 shares during the period. Finally, FMR LLC boosted its holdings in Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after buying an additional 3,075,019 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.4 %

Shares of NYSE:KVUE opened at $21.11 on Friday. The company has a market cap of $40.46 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a fifty day moving average price of $22.42 and a two-hundred day moving average price of $21.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same period last year, the business earned $0.31 EPS. Kenvue’s quarterly revenue was down .4% compared to the same quarter last year. Analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.89%. Kenvue’s dividend payout ratio is currently 149.09%.

Analysts Set New Price Targets

A number of analysts recently commented on KVUE shares. Jefferies Financial Group initiated coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. UBS Group lowered their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday. JPMorgan Chase & Co. boosted their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Citigroup lowered their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.